在作用过程中，3种细胞因子像一支协同作战的"爆破小队"。干扰素γ负责"引路"，指引关键的打孔蛋白 前往胰腺癌细胞内的溶酶体；干扰素β提供"爆破工具"，激活打孔蛋白；转化生长因子β则是"稳定器"， 确保打孔蛋白保持维持激活状态。最终，打孔蛋白在溶酶体膜上打出孔洞，癌细胞随之从内部被彻 底"爆破"瓦解。 胰腺癌俗称"癌中之王"，恶性程度极高，治疗难度大，长期缺乏有效治疗手段。中国医学科学院基础医 学研究所教授黄波团队发现，胰腺癌细胞表面会形成一层黏液保护层，既能够逃避免疫细胞的攻击，也 能抵抗人体自身消化酶的清除，这是导致胰腺癌难以治疗的重要原因。3种细胞因子联合使用能够突破 这层屏障，激活胰腺癌细胞内部的死亡机制。 中国医学科学院团队近日发布一项研究成果，首次证实联合使用3种常见细胞因子，能够有效破坏胰腺 癌细胞内部结构，使癌细胞"炸裂"死亡，为胰腺癌治疗提供了新思路。 团队表示，该研究不仅揭示了3种细胞因子在胰腺癌治疗中的协同机制，也为临床转化提供了可行路 径，有望攻克胰腺癌治疗的医学难题。 来源：北京日报客户端 研究还提出，借助脂质纳米颗粒载体，可将这3种细胞因子的信使核糖核酸精准输送至肿瘤部位，既能 提高 ...

Core Viewpoint - The company, Hutchison China MediTech Limited (和黄医药), has initiated the Phase III portion of a clinical trial for surufatinib in combination with camrelizumab, nab-paclitaxel, and gemcitabine for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) patients in China, with the first patient receiving treatment on December 30, 2025 [1]. Group 1 - The study is a multicenter, randomized, open-label, positive-controlled Phase II/III clinical trial aimed at evaluating the efficacy and safety of the S+C+AG regimen compared to the AG regimen in adult patients with metastatic pancreatic cancer who have not previously received systemic anti-tumor therapy [2]. - The Phase II portion of the study included 62 patients, with plans to enroll approximately 400 additional patients in the Phase III portion [2]. - The primary endpoint of the Phase III portion is overall survival (OS), while secondary endpoints include progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), quality of life, and safety [2]. Group 2 - Results from the Phase II portion were recently presented at the 2025 European Society for Medical Oncology (ESMO) Asia Congress, showing a median PFS of 8.15 months as of the data cutoff on July 24, 2025 [3]. - The S+C+AG group had a median PFS of 7.20 months compared to 5.52 months for the AG group, indicating a 50.1% reduction in the risk of disease progression or death (HR 0.499, p=0.0407) [3]. - Other key efficacy endpoints showed similar benefits, with an ORR of 67.7% versus 41.9% (p=0.0430) and a DCR of 93.5% versus 71.0% (p=0.0149) [3]. - Although overall survival data is not yet mature, a positive trend has been observed, with 9 events in the S+C+AG group and 15 events in the AG group [3]. - The treatment demonstrated manageable safety characteristics, with 80.6% of patients in the S+C+AG group experiencing grade 3 or higher treatment-emergent adverse events (TEAEs), compared to 61.3% in the AG group [3].

Core Insights - The article discusses a significant advancement in the treatment of resectable pancreatic cancer through a randomized phase 3 trial, highlighting the efficacy of a sequential neoadjuvant therapy compared to direct surgery [2][3][8]. Group 1: Study Overview - The study involved 324 patients with resectable pancreatic cancer, comparing the outcomes of a sequential neoadjuvant treatment regimen against immediate surgery [3][4]. - The neoadjuvant therapy consisted of nab-paclitaxel combined with gemcitabine, followed by modified FOLFIRINOX, aimed at reducing tumor size and improving surgical outcomes [4][5]. Group 2: Results - The neoadjuvant treatment group demonstrated a median event-free survival of 15.3 months, compared to 10.9 months for the direct surgery group, with a hazard ratio of 0.71 [6]. - The median overall survival was 35.4 months for the neoadjuvant group versus 27.2 months for the direct surgery group, with a hazard ratio of 0.73 [6]. - Adverse events of grade 3 or higher occurred in 47.6% of the neoadjuvant group and 30.7% of the direct surgery group, indicating manageable safety profiles for the new treatment [6]. Group 3: Implications - The findings suggest that the sequential neoadjuvant therapy significantly improves event-free survival and offers a new treatment option for patients with resectable pancreatic cancer [8].

Core Insights - The article discusses the critical role of Osteopontin (SPP1), BMP2, and GREM1 in regulating pancreatic cancer cell fate, proposing a novel therapeutic strategy targeting SPP1 to reverse pancreatic cancer progression [3][25]. Group 1: Pancreatic Cancer Overview - Pancreatic ductal adenocarcinoma is the most common and lethal type of pancreatic cancer, with a one-year survival rate of approximately 25% and a five-year survival rate of less than 5% [2]. - The disease is characterized by high heterogeneity and a complex tumor microenvironment, making treatment particularly challenging [2]. Group 2: Key Findings on SPP1 - The study reveals that SPP1, BMP2, and GREM1 play a central role in regulating pancreatic cancer cell fate [3]. - Elevated levels of SPP1 were found in late-stage pancreatic cancer patients, with significant implications for prognosis [5][6]. - High SPP1 expression correlates with worse outcomes in pancreatic cancer patients, indicating its potential as a biomarker and a direct participant in tumor progression [7]. Group 3: Mechanistic Insights - SPP1 interacts with the receptor CD61 on mesenchymal tumor cells, activating the NF-κB signaling pathway, which in turn regulates BMP2 and GREM1 expression [19]. - The communication between epithelial and mesenchymal tumor cells is described as a "telegram," with SPP1 and GREM1 acting as key signaling molecules [19][21]. Group 4: Experimental Models and Results - The research team developed genetically engineered mouse models to study the role of SPP1 in pancreatic cancer, demonstrating that knocking out SPP1 significantly reduced tumor progression and extended survival [12][14][26]. - The KPCY mouse model, which closely mimics human pancreatic cancer mutations, showed that targeting SPP1 with monoclonal antibodies effectively prolonged survival and inhibited metastasis without significant side effects [26]. Group 5: Multidisciplinary Collaboration - The study integrates clinical medicine, biophysics, and molecular biology, providing a comprehensive understanding of pancreatic cancer biology and laying the groundwork for new therapeutic strategies [29].

Core Insights - Beijing Shengnuo Pharmaceutical Technology Co., Ltd. received approval for clinical trials of its product, Icariin Soft Capsule, in combination with AG regimen for treating locally advanced unresectable or metastatic pancreatic cancer [1] Group 1: Clinical Trial Approval - The National Medical Products Administration approved the clinical trial for Icariin Soft Capsule in combination with albumin-bound paclitaxel and gemcitabine for pancreatic cancer treatment [1] - Pancreatic cancer has a low 5-year survival rate of less than 10%, with most patients diagnosed at an advanced stage [1] Group 2: Research Findings - A study from Zhejiang University included 20 newly diagnosed patients with advanced pancreatic ductal adenocarcinoma (PDAC), showing an objective response rate (ORR) of 50% and a disease control rate (DCR) of 90% [1] - The 6-month survival rate was reported at 90%, with 35% of initially unresectable patients becoming resectable after treatment [1] - The results indicate significant potential for Icariin in combination chemotherapy for pancreatic cancer [1] Group 3: Collaborative Research - Shengnuo Pharmaceutical collaborated with Nankai University and Peking University Cancer Hospital to conduct in vitro experiments using organoids from pancreatic cancer patients [2] - The experiments confirmed significant synergistic effects of Icariin with first-line treatments (gemcitabine + albumin-bound paclitaxel) and (albumin-bound paclitaxel + PD-1 antibody) [2] - Icariin was observed to promote T cell migration towards tumor organoids, further validating clinical synergistic results and providing a basis for upcoming clinical trials [2]

Core Viewpoint - The company announced preliminary data from a Phase II clinical study of TQB2868, a PD-1/TGF-β dual-function fusion protein, in combination with Anlotinib and chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the 2025 ASCO annual meeting [1] Group 1: Clinical Study Results - The study has enrolled 40 patients with stage IV mPDAC, with 36 patients being evaluable as of January 2025 [1] - The objective response rate (ORR) for TQB2868 combined with Anlotinib and AG chemotherapy reached 63.9%, which is 2-3 times higher than historical data for AG chemotherapy [1] - The disease control rate (DCR) was 100%, 1.6 times higher than that of AG chemotherapy [1] - The median progression-free survival (PFS) has not yet been reached, but the 6-month PFS rate is 86%, which is double that of AG chemotherapy [1] - The median overall survival (OS) has not yet been reached, but it is expected to exceed one year [1] Group 2: Safety Profile - The combination therapy demonstrated good safety and tolerability, with a rate of grade 3 or higher adverse reactions at 52.5% [1] - The company is in communication with the Center for Drug Evaluation (CDE) of the National Medical Products Administration regarding the registration of a Phase III clinical trial for the TQB2868 combination therapy [1]